BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1779 related articles for article (PubMed ID: 18075247)

  • 1. Oxidized low-density lipoprotein biomarkers in patients with end-stage renal failure: acute effects of hemodialysis.
    Bossola M; Tazza L; Merki E; Giungi S; Luciani G; Miller ER; Lin EB; Tortorelli A; Tsimikas S
    Blood Purif; 2007; 25(5-6):457-65. PubMed ID: 18075247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OxPL/apoB, lipoprotein(a) and OxLDL biomarkers and cardiovascular disease in chronic hemodialysis patients.
    Bossola M; Tazza L; Luciani G; Tortorelli A; Tsimikas S
    J Nephrol; 2011; 24(5):581-8. PubMed ID: 21404224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
    Fraley AE; Schwartz GG; Olsson AG; Kinlay S; Szarek M; Rifai N; Libby P; Ganz P; Witztum JL; Tsimikas S;
    J Am Coll Cardiol; 2009 Jun; 53(23):2186-96. PubMed ID: 19497447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein.
    Tsimikas S; Lau HK; Han KR; Shortal B; Miller ER; Segev A; Curtiss LK; Witztum JL; Strauss BH
    Circulation; 2004 Jun; 109(25):3164-70. PubMed ID: 15184281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial.
    Tsimikas S; Witztum JL; Miller ER; Sasiela WJ; Szarek M; Olsson AG; Schwartz GG;
    Circulation; 2004 Sep; 110(11):1406-12. PubMed ID: 15353498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin.
    Rodenburg J; Vissers MN; Wiegman A; Miller ER; Ridker PM; Witztum JL; Kastelein JJ; Tsimikas S
    J Am Coll Cardiol; 2006 May; 47(9):1803-10. PubMed ID: 16682304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study.
    Tsimikas S; Kiechl S; Willeit J; Mayr M; Miller ER; Kronenberg F; Xu Q; Bergmark C; Weger S; Oberhollenzer F; Witztum JL
    J Am Coll Cardiol; 2006 Jun; 47(11):2219-28. PubMed ID: 16750687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans.
    Ky B; Burke A; Tsimikas S; Wolfe ML; Tadesse MG; Szapary PO; Witztum JL; FitzGerald GA; Rader DJ
    J Am Coll Cardiol; 2008 Apr; 51(17):1653-62. PubMed ID: 18436117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study.
    Kiechl S; Willeit J; Mayr M; Viehweider B; Oberhollenzer M; Kronenberg F; Wiedermann CJ; Oberthaler S; Xu Q; Witztum JL; Tsimikas S
    Arterioscler Thromb Vasc Biol; 2007 Aug; 27(8):1788-95. PubMed ID: 17541022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxidized low-density lipoprotein autoantibodies, chronic infections, and carotid atherosclerosis in a population-based study.
    Mayr M; Kiechl S; Tsimikas S; Miller E; Sheldon J; Willeit J; Witztum JL; Xu Q
    J Am Coll Cardiol; 2006 Jun; 47(12):2436-43. PubMed ID: 16781371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Body mass index and cardiovascular risk factors and biomarkers in hemodialysis patients.
    Bossola M; Giungi S; Panocchia N; Vulpio C; Luciani G; Tazza L
    J Nephrol; 2008; 21(2):197-204. PubMed ID: 18446714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Electronegative LDL and lipid abnormalities in patients undergoing hemodialysis and peritoneal dialysis.
    Lobo J; Santos F; Grosso D; Lima R; Barreira AL; Leite M; Mafra D; Abdalla DS
    Nephron Clin Pract; 2008; 108(4):c298-304. PubMed ID: 18434752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice.
    Merki E; Graham MJ; Mullick AE; Miller ER; Crooke RM; Pitas RE; Witztum JL; Tsimikas S
    Circulation; 2008 Aug; 118(7):743-53. PubMed ID: 18663084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure.
    Holvoet P; Donck J; Landeloos M; Brouwers E; Luijtens K; Arnout J; Lesaffre E; Vanrenterghem Y; Collen D
    Thromb Haemost; 1996 Nov; 76(5):663-9. PubMed ID: 8950769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of oxidized phospholipids, lipoprotein (a) and biomarkers of oxidized lipoproteins in chronically occluded coronary arteries in sudden cardiac death and following successful percutaneous revascularization.
    Fefer P; Tsimikas S; Segev A; Sparkes J; Otsuka F; Kolodgie F; Virmani R; Juliano J; Charron T; Strauss BH
    Cardiovasc Revasc Med; 2012; 13(1):11-9. PubMed ID: 22079685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heritability of Biomarkers of Oxidized Lipoproteins: Twin Pair Study.
    Rao F; Schork AJ; Maihofer AX; Nievergelt CM; Marcovina SM; Miller ER; Witztum JL; O'Connor DT; Tsimikas S
    Arterioscler Thromb Vasc Biol; 2015 Jul; 35(7):1704-11. PubMed ID: 25953646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aged garlic extract supplemented with B vitamins, folic acid and L-arginine retards the progression of subclinical atherosclerosis: a randomized clinical trial.
    Budoff MJ; Ahmadi N; Gul KM; Liu ST; Flores FR; Tiano J; Takasu J; Miller E; Tsimikas S
    Prev Med; 2009; 49(2-3):101-7. PubMed ID: 19573556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed in vivo catabolism of intermediate-density lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis.
    Ikewaki K; Schaefer JR; Frischmann ME; Okubo K; Hosoya T; Mochizuki S; Dieplinger B; Trenkwalder E; Schweer H; Kronenberg F; Koenig P; Dieplinger H
    Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2615-22. PubMed ID: 16195474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular risk factors in hemodialysis and peritoneal dialysis patients.
    Helal I; Smaoui W; Hamida FB; Ouniss M; Aderrahim E; Hedri H; Elyounsi F; Maiz HB; Abdallah TB; Kheder A
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):59-62. PubMed ID: 20061694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Raised plasma total sialic acid levels are markers of cardiovascular disease in renal dialysis patients.
    Afzali B; Bakri RS; Bharma-Ariza P; Lumb PJ; Dalton N; Turner NC; Wierzbicki AS; Crook MA; Goldsmith DJ
    J Nephrol; 2003; 16(4):540-5. PubMed ID: 14696756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 89.